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ABSTRACT 
 
Introduction: Polycystic ovary syndrome (PCOS) is a common endocrine condition, with known 
variability in the severity of its cardinal features and long-term health consequences across races 
and ethnicities. Diagnosis of PCOS involves the ultrasonographic identification of polycystic 
ovarian morphology (PCOM). However, current diagnostic thresholds for PCOM do not account 
for any impact of race or reflect the potential for race-specific differences in the presentation of 
PCOS. I aimed to evaluate differences in ovarian morphology between South Asian and White 
women with PCOS and assess relationships between reproductive / metabolic features and PCOM 
in both cohorts. Methods: White (n = 30) and South Asian (n = 31) women with PCOS underwent 
clinical evaluation, venipuncture, and transvaginal ultrasonography. Markers of PCOM (i.e., 
follicle number per ovary [FNPO] and ovarian volume [OV]) and reproductive / metabolic status 
were compared between groups. Results: South Asian women with PCOS had lower OV (9.0 vs. 
12.5 mL, P < 0.01) and slightly lower FNPO (31 vs. 44 follicles, P = 0.06) than White women 
with PCOS. South Asian women also had more metabolic disturbances than White women, as 
indicated by higher waist circumference, waist-to-hip ratio, and 2-hour glucose levels (All: P < 
0.05). Correlations between ovarian morphology and reproductive / metabolic features were 
variable across cohorts and challenging to interpret due to limited sample sizes. Conclusions: My 
findings support the need for race-specific diagnostic criteria for PCOM. Future studies would 
benefit from the inclusion of larger cohorts of South Asian and White women to clarify the 
importance of race in the manifestation and treatment of PCOS.  
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INTRODUCTION  
 
Polycystic Ovary Syndrome. Polycystic ovary syndrome (PCOS) is a complex endocrine condition 
that affects 8–13% of premenopausal women worldwide.1 PCOS is heterogeneous in nature and 
characterized by a combination of three cardinal features: (1) hyperandrogenism, (2) menstrual 
irregularities, and (3) polycystic ovarian morphology (PCOM) on ultrasonography.2 The condition 
is not well understood, because the etiology is unclear and the phenotypic presentation varies with 
age, race, ethnicity, and physiologic factors (i.e., adiposity and androgen status).3 PCOS is linked 
to metabolic comorbidities, including obesity, insulin resistance, inflammation, hypertension, and 
dyslipidemia,4 which can increase the risk for infertility, adverse pregnancy outcomes, 
cardiovascular disease, diabetes mellitus, stroke, and certain gynecological cancers.3 Many 
patients also experience an array of psychological issues including poor quality of life, low self-
esteem, anxiety, and depression.5 Because the reproductive, metabolic, and psychological 
comorbidities have serious implications for women and their families, it is critical to establish 
diagnostic criteria that accurately identify those with PCOS and allow for early prescription of 
preventative therapies. 
 
Diagnosis of PCOS. Due to its complex and likely multi-factorial etiology, the diagnostic criteria 
for PCOS have been changed and heavily debated over time. The diagnosis not only involves an 
identification of the cardinal features, but exclusion of other disorders that manifest like PCOS 
(e.g., thyroid disorders, congenital adrenal hyperplasia, and androgen-secreting tumors).6,7 Three 
sets of diagnostic criteria for PCOS have been published to date and are summarized in Table 1. 
In 1990, the National Institute of Child Health and Human Development (NICHD) proposed that 
 4 
the definition of PCOS include evidence of hyperandrogenism and menstrual irregularities, but not 
PCOM.8 Many experts believed that PCOM was not necessary for the diagnosis of PCOS, because 
anecdotal reports estimated that 30% of patients did not have the ovarian phenotype.8 However, it 
soon became clear that the condition was much broader than what the NICHD definition allowed 
and that women could exhibit signs of ovarian dysfunction despite normal androgen status.9 In 
2003, the Rotterdam PCOS Consensus Workshop Group (hosted by the American Society for 
Reproductive Medicine and the European Society for Human Reproduction and Embryology) 
proposed that the presence of any two of the three cardinal features (i.e., hyperandrogenism, 
menstrual irregularities, or PCOM) was sufficient for the diagnosis of PCOS.9 The “Rotterdam” 
criteria expanded the range of possible clinical phenotypes and increased the number of women 
that could be classified as having PCOS. Then, in 2006, the Androgen Excess and PCOS (AE-
PCOS) Society re-assessed whether the broadened definition captured the true population of 
women with PCOS or instead overestimated the prevalence.10 The AE-PCOS Society ultimately 
emphasized that PCOS is a disorder of androgen excess and cannot be identified in its absence.11 
Together, recognition of different diagnostic criteria for PCOS has resulted in variable global 
estimates of the prevalence of PCOS and obscured our understanding of the pathogenesis of the 
condition.12 In an effort to standardize methods for diagnosing and treating PCOS, Teede et al. 
recently published the first International Evidence-based Guideline for the Assessment and 
Management of PCOS in 2018. Based on expert opinion and the benefits of studying all existing 
variants of PCOS, the authors’ supported the sole use of the Rotterdam criteria in both clinical 
practice and research.1 
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Table 1. Diagnostic Criteria for PCOS 
 NICHD (1990)8 Rotterdam (2003)9 AE-PCOS (2006)10 
Hyperandrogenism Required Optional Required 
Menstrual irregularities Required Optional Optional 
PCOM  Optional Optional 
Notes Ignores PCOM Requires  2 of 3 features 
Requires 
hyperandrogenism 
Adapted from Lujan et al. 2008.7 Abbreviations: PCOM, polycystic ovarian morphology; NICHD, National Institute 
of Child Health and Human Development; AE-PCOS, Androgen Excess and PCOS. 
 
Definition of PCOM. Inclusion of the ovary in the diagnostic criteria for PCOS requires an 
accurate definition for PCOM. PCOM is characterized by follicular excess and increased ovarian 
size compared to normal ovaries.13 Although recent technological advances have facilitated the 
detection of discrete aspects of ovarian morphology, differences in equipment and operator skills 
across healthcare centers have prevented diagnostic thresholds for ultrasonographic markers from 
being universally agreed upon.13 Debates have centered on the thresholds beyond which follicle 
number and ovarian size should be regarded as “abnormal.” The Rotterdam criteria included the 
first-ever ultrasonographic definition of PCOM, i.e., the presence of ³ 12 follicles (2 – 9 mm in 
diameter) in the entire ovary (FNPO) and/or ovarian volume (OV) ³ 10 mL.13 FNPO ³ 12 was 
initially accepted and widely used in clinical practice and research, but is now no longer seen as 
valid.14 Its use led to an over-diagnosis of PCOM in healthy women due to the increased 
visualization of smaller follicles with newer imaging technology (e.g., 2 – 4 mm).15 Higher 
thresholds have been proposed for FNPO in the past five years (Table 2), with Dewailly et al. and 
Lujan et al. publishing the best-designed diagnostic test studies in the field to date. Using high 
frequency ultrasound transducers and receiver operating characteristic curve analysis, the two 
groups observed that FNPO ³ 19 and ³ 26, respectively, offered the best diagnostic potential for 
PCOS.15,16 In 2014, the AE-PCOS Society Task Force reaffirmed a threshold for FNPO of ³ 25, 
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by considering the upper limit of follicle counts in a healthy control population.14 The AE-PCOS 
Task Force also concluded that FNPO is the most reliable metric of PCOM and PCOS, and 
suggested that OV only be used in cases of reduced image quality.14 Then, in 2018, Teede and 
colleagues recommended a threshold for FNPO of ³ 201 based on expert opinion (Table 2). 
Notably, although higher thresholds for FNPO aim to reduce the misdiagnosis of PCOM, they 
remain limited by the lack of attention to the demographic and physiologic factors that modify the 
presentation of the syndrome.  
 
Table 2. Summary of Proposed Thresholds to Define PCOM by FNPO and OV 
Group Year Country of Origin N FNPO  OV (mL) 
Rotterdam9 2003 France C: 112 P: 214 ³ 12 ³ 10 
Dewailly et al.16 2011 France C: 105 P: 62 ³ 19 N/A 
Lujan et al.15 2013 North America C: 70 P: 98 ³ 26 ³ 10 
AE-PCOS Task Force14 2014 International C: >1000 P: N/A ³ 25 ³ 10 
International Guideline1 2018 International C: NR P: N/A ³ 20 ³ 10 
Across publications, the thresholds for FNPO and OV were not determined with the same ultrasound technology or 
methodology. Efforts to standardize technology and methodology are ongoing in the field of PCOS. Abbreviations: 
N, sample size; FNPO, follicle number per ovary; OV, ovarian volume; C, Control; P, PCOS; N/A, not assessed; NR, 
not reported. 
 
Race, Ethnicity, and PCOM. Race and ethnicity are believed to play a role in the presentation of 
PCOM.1,3,14  Previous diagnostic test studies have derived thresholds for FNPO and OV from 
cohorts of predominantly White women in Europe and North America (Table 2). Some authors 
have argued that such approaches are not adequate to detect PCOM in other populations and have 
pointed to the need for race- or ethnicity-specific thresholds.17,18,19,20 Four groups have performed 
diagnostic test studies in Asian cohorts and the results are listed in Table 3. Proposed thresholds 
have ranged from FNPO ³ 8 in Turkish women18 to FNPO ³ 12 in Chinese17 and Indian20 women. 
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Thresholds for OV have ranged from ³ 6 to ³ 8 mL.17,18,19,20 Of the two studies that have considered 
PCOM in Indian women, each one has identified a different threshold for FNPO and OV. Ahmed 
et al. proposed an FNPO ³ 9 and OV ³ 8 mL,19 while Kar et al. proposed an FNPO ³ 12 and OV 
³ 6 mL20 (Table 3). Together, existing data support the notion that ovarian morphology may differ 
sufficiently across races and ethnicities, wherein application of current international consensus 
thresholds for PCOM may not be reliable for the ultrasound diagnosis of PCOS in all women. 
However, to the best of my knowledge, no studies have directly compared PCOM across women 
of different races. Given the variability in proposed thresholds for Indian cohorts, such studies are 
needed to quantify the actual degree to which ovarian morphology differs in White versus South 
Asian women with PCOS. 
 
Table 3. Summary of Proposed Thresholds to Define PCOM in Asian Countries 
Group Year Race Country of Origin N FNPO  OV (mL) 
Chen17 2008 Asian China C: 153 P: 432 ³ 12 ³ 8 
Köşüş18 2011 Asian Turkey C: 65 P: 251 ³ 8 ³ 6 
Ahmed19 2014 Asian India C: 77 P: 119 ³ 9 ³ 8 
Kar20 2018 Asian India C: 45 P: 86 ³ 12 ³ 6 
Abbreviations: N, sample size; FNPO, follicle number per ovary; OV, ovarian volume; C, control; P, PCOS. 
 
Impact of Race and Ethnicity on the Presentation of PCOS. Previous studies have reported racial 
and ethnic differences in the presentation of PCOS, including in the severity of hirsutism and the 
prevalence of co-morbid metabolic disorders.21–24 A large international cross-sectional study found 
that Asian women with PCOS from India have higher modified hirsutism scores than White 
women with PCOS from Europe and North America.23 Indian women with PCOS also have 
increased fasting insulin,24 greater insulin responses to a glucose challenge,24 and a heightened 
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prevalence of metabolic syndrome compared to White women with PCOS.23 Different features 
appear to contribute to the heightened prevalence of metabolic syndrome in Indian women – 
particularly a higher prevalence of obesity, elevated fasting glucose levels, and low HDL.23 
Similarly, a recent systematic review concluded that Asian women with PCOS exhibit the highest 
risk of impaired glucose tolerance compared to White women with PCOS, even when cohorts are 
matched for body mass index (BMI).22,23 Interestingly, genetic factors may not explain racial or 
ethnic differences in the severity of PCOS. Previous genome-wide associations studies have shown 
that the genetic determinants of metabolic syndrome are similar in Indian and European men.25 In 
addition, susceptibility loci for PCOS have not differed between Han Chinese and European 
women, suggesting that the genetic risk for the condition is similar across races and ethnicities.26–
28 Such findings support the notion that other factors, including differences in lifestyle or 
environment, could be involved in the mechanism behind racial and ethnic differences in the 
severity of PCOS. Studies that compare the severity of PCOS by country of origin and country of 
residence might help to clarify the environmental versus genetic contributions to racial and ethnic 
differences. Nevertheless, if metabolic disorders are more prevalent in South Asian than White 
women, then there is an even greater need to refine the ultrasound criteria for PCOS to ensure 
reliable early evaluation and treatment.23 
 
Utility of Ultrasound Beyond the Diagnosis of PCOS. It should be acknowledged that ovarian 
morphology may be able to provide information beyond the diagnosis of PCOS. In particular, 
PCOM may also reflect the severity of a patient’s reproductive and metabolic disturbances. We 
previously showed that the number of total follicles (2 – 9 mm diameter) and small antral follicles 
(3 – 4 mm) in the ovaries were positively associated with androgen concentrations in women with 
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PCOS, while the number of medium-sized follicles (5 – 6 mm) was positively associated with both 
androgens and menstrual cycle length. Smaller follicles (£ 4 mm) were also negatively linked to 
BMI, waist-to-hip ratio, and markers of insulin resistance.29 Further, the number of medium and 
large follicles (5 – 11 mm) were positively associated with features of metabolic health, but 
negatively associated with aspects of reproductive disturbance in PCOS.29 In a second report, we 
showed that women with PCOS who developed dominant follicles (≥ 10 mm) had lower BMIs and 
improved glucoregulation compared to women that did not develop dominant follicles.30,31 Such 
information may be useful in clinics that can afford the one-time purchase of an ultrasound 
machine, but have limited financial resources to purchase multiple endocrine and metabolic assays. 
Some blood tests may not be covered by patients’ insurance companies or may not be available in 
rural areas. If both the diagnosis of PCOM and an indication of metabolic status can be garnered 
from a single ultrasound scan, then there may be an opportunity to improve the accessibility of 
care and identify patients that would not otherwise be treated for metabolic issues (e.g., younger 
or normal-weight women with PCOS). The role of ultrasonography for triaging medical care in 
women may be especially important in lower-income countries like India.  
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AIMS AND HYPOTHESES 
 
Overall, there is little information on the differences in ovarian morphology between White and 
South Asian women with PCOS and whether or how these differences might reflect reproductive 
or metabolic status. My objectives were to: (1) evaluate differences in ovarian morphology 
between South Asian and White women with PCOS, and (2) assess any relationships between 
reproductive / metabolic features and PCOM in both cohorts. Based on the studies referenced in 
Table 3, I hypothesized that estimates of FNPO and OV would be lower in South Asian women 
with PCOS compared to White women with PCOS. Likewise, based on our previous observations 
in White women,29 I hypothesized that correlations of similar direction, but different magnitude 
would be found between reproductive / metabolic features and PCOM in the South Asian and 
White cohorts. The present work is especially timely, given the recent calls to action to consider 
race and ethnicity in the diagnosis and treatment of PCOS.1,3,14   
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METHODS 
 
Study Population. The present study involved the secondary analysis of data from (a) clinical 
research studies conducted in New York State, United States (White women with PCOS) and (b) 
patient medical charts and ultrasound images shared by a gynecologic primary care center in 
Odisha, India (South Asian women with PCOS). Data collection for the clinical research studies 
occurred at Cornell University and the University of Rochester from 2010 to 2018. The original 
study protocols were approved by the Institutional Review Boards at both universities 
(ClinicalTrials.gov Identifiers: NCT01927471, NCT01859663, NCT01927432, NCT01785719). 
In all cases, written, informed consent was obtained before the study procedures were initiated. 
White women were selected for inclusion in the present analysis from a database of past 
participants (n = 220). Women were excluded if they: (1) were not of reproductive age (i.e., <18 
or >38 years) (n = 11); (2) did not self-identify as both Non-Hispanic and White (n = 96); (3) were 
using hormonal contraception or medications known to interfere with glucose or lipid metabolism 
(n = 7); (4) did not provide sufficient clinical and ultrasonographic data to assess the endpoints of 
interest (n = 14); (5) were evaluated in the pre-ovulatory or luteal phase of the menstrual cycle (n 
= 3); (6) were evaluated with transabdominal, instead of transvaginal, ultrasonography (n = 0); (7) 
had abnormal thyroid-stimulating hormone or prolactin levels (n = 0); or (8) did not have PCOS 
based on the NICHD criteria (as described below; n = 59).8 The remaining cohort included 30 
White women with PCOS. Medical charts were obtained from consecutive patients seen at the 
primary care center in India from January to May 2018 (n = 67). The retrospective chart reviews 
were confirmed to be an exempt research activity by Cornell’s Institutional Review Board. As with 
the White cohort, South Asian women were excluded from the present analysis if they: (1) did not 
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provide sufficient clinical and ultrasonographic data to assess the endpoints of interest (n = 16); 
(2) were evaluated in the pre-ovulatory or luteal phase of the menstrual cycle (n = 1); (3) were 
evaluated with transabdominal, instead of transvaginal, ultrasonography (n = 18); or (4) did not 
have PCOS based on the NICHD criteria (as described below; n = 1).8 The remaining cohort 
included 31 South Asian women with PCOS. For both cohorts, I elected to rely on self-reported 
race, due to evidence that an individual’s identification with a particular racial category is highly 
reliable.32 
 
Clinical Definition of PCOS. Women in both cohorts were retrospectively categorized as having 
PCOS according to the NICHD criteria.8 The NICHD criteria were used to allow for unbiased 
comparisons of ovarian morphology between groups. Menstrual cycle length was assessed 
categorically (i.e., as being 21 – 35 or ³ 36 days apart). Women that reported menstrual cycles ³ 
36 days apart were considered to have menstrual irregularities. Clinical androgen status was 
evaluated with modified hirsutism score, or male-patterned hair growth on nine regions of the body, 
according to the Ferriman-Gallwey Scale.33 Biochemical androgen status was judged with serum 
total testosterone concentration. Women with elevated modified hirsutism scores (³ 7) or serum 
total testosterone concentrations (i.e., ³ 61.5 ng/dL in the White cohort or ³ 76.0 ng/dL in the 
South Asian cohort) were considered to have hyperandrogenism. The same thresholds were used 
to assess menstrual cycle length and hirsutism in both cohorts due to limited data detailing 
differences in the features between White and South Asian women. However, different thresholds 
were employed for total testosterone in each cohort due to the use of separate, non-comparable 
assays between sites. Descriptions of the assays used to measure total testosterone are listed in 
Table 4. 
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Measurement of Reproductive and Metabolic Features. Reproductive and metabolic endpoints 
were evaluated by anthropometry (for height, weight, and waist and hips circumference), vitals 
assessment (for systolic and diastolic blood pressure), and 75-gram 2-hour oral glucose tolerance 
tests (OGTT). Clinical procedures were conducted using internationally standardized approaches 
at both sites.34 Waist-to-hip ratio was calculated as the ratio of waist circumference (cm) to hips 
circumference (cm), and BMI was calculated by the ratio of weight (kg) to height squared (m2). 
Blood samples were obtained before (i.e., at fasting or 0 hours) and after the OGTT (i.e., at 2 
hours). Fasting samples were assayed for circulating glucose, total testosterone, and anti-Müllerian 
hormone (AMH) concentrations, and 2-hour samples were assayed for glucose (Table 4). Given 
the retrospective nature of the present study’s design, the use of different biochemical assays at 
each site could not be avoided. I also acknowledge the potential for inter-site differences in the 
assessment of menstrual cycle length, hirsutism, anthropometry, and vitals. Therefore, to be as 
conservative as possible in group comparisons, all reproductive and metabolic endpoints were 
judged categorically between cohorts (i.e., “normal” or “abnormal” values), based on variable- and 
assay-specific reference ranges (Table 4).  
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Table 4. Clinical and biochemical methodologies and normal reference ranges for each cohort    
Endpoint Methodology Normal Range Abnormal Range Intra-Assay CV (%) 
Inter-Assay 
CV (%) 
White women with PCOS (United States) 
Menstrual cycle length (d)1 Self-report 21 – 35 ≥ 36 N/A N/A 
Modified hirsutism score Ferriman-Gallwey Scale33  0 – 6 ≥ 7 N/A N/A 
Total testosterone (ng/dL) LC/MS/MS < 61.5 ≥ 61.5 < 8 < 5 
AMH (ng/dL) ELISA 0.2–16.0 < 0.2 or > 16.0 < 7 < 7 
BMI (kg/m2)35  Standard approaches 18.5–24.9  ≥ 25.0 N/A N/A 
Waist circumference (cm)35  Standard approaches < 80 ≥ 80 N/A N/A 
Waist-to-hip ratio35 Standard approaches < 0.85 ≥ 0.85 N/A N/A 
Blood pressure (mmHg)35 Standard approaches < 140/90 ≥ 140/90 N/A N/A 
Glucose, 0-hour (mg/dL)36 Glucometer < 100 ≥ 100 N/A N/A 
Glucose, 2-hour (mg/dL)36 Glucometer < 140 ≥ 140 N/A N/A 
South Asian women with PCOS (India) 
Menstrual cycle length (d)1 Self-report 21 – 35 ≥ 36 N/A N/A 
Modified hirsutism score Ferriman-Gallwey Scale33  0 – 6 ≥ 7 N/A N/A 
Total testosterone (ng/dL) CLIA < 76.0 ≥ 76.0 < 5 < 5 
AMH (ng/dL) ELFA 1 – 10 > 10 < 9 < 9 
BMI (kg/m2)35 Standard approaches 18.5–24.9  ≥ 25.0 N/A N/A 
Waist circumference (cm)35 Standard approaches < 80 ≥ 80 N/A N/A 
Waist-to-hip ratio35 Standard approaches < 0.85 ≥ 0.85 N/A N/A 
Blood pressure (mmHg)35 Standard approaches < 140/90 ≥ 140/90 N/A N/A 
Glucose, 0-hour (mg/dL)36 GOD-POD < 100 ≥ 100 < 3 < 3 
Glucose, 2-hour (mg/dL)36 GOD-POD < 140 ≥ 140 < 3 < 3 
Abbreviations:  BMI, body mass index; AMH, anti-Müllerian hormone; LC/MS/MS, liquid-chromatography tandem mass spectrometry; ELISA, enzyme-linked 
immunosorbent assay; CLIA, chemiluminescence immunoassay; ELFA, enzyme-linked immunofluorescent assay; GOD-POD, glucose oxidase and peroxidase; 
CV, coefficient of variation; N/A, not applicable.
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Transvaginal Ultrasonography and Ovarian Image Analysis. Ultrasound examinations were 
conducted in the United States for White women with PCOS and in India for South Asian women 
with PCOS. Across clinical research centers and countries, ovaries were assessed using a GE 
Voluson ultrasound machine (i.e., E8 Expert, S6, or S10 Series) and 5 – 9 (n = 6) or 6 – 12 MHz 
endovaginal transducer (n = 55) (GE Healthcare, Milwaukee, WI). To the best of our knowledge, 
ultrasound machine brand and series are unlikely to influence estimates of follicle number or 
ovarian size. Examinations were conducted during the early follicular phase (i.e., in the absence 
of follicles > 13 mm) and on the same day as all other endpoints were collected. Three-dimensional 
volumes of each ovary were obtained using customized settings and the automated volume 
modality, in order to simultaneously collect data in the sagittal and transverse anatomical planes. 
Two-dimensional cineloops were then extracted by individually partitioning each plane (Slice 
Thickness: 0.5 mm) and then archived for offline analysis with Santesoft DICOM Editor Medical 
Imaging Software (Sante DICOM Editor, Santesoft LTD, Athens, Greece). Image analyses were 
conducted by investigators at Cornell University, regardless of the site of data collection, to 
minimize variability in estimates of ovarian morphology. Endpoints of interest included: FNPO, 
follicle number per cross-section (FNPS), and OV. Reliable estimates of FNPO (i.e., FNPO2–9mm) 
were obtained using the grid system method, as previously described by Lujan et al.37 Follicles 
were measured and categorized as either small (i.e., FNPO2–5mm) or medium-sized (i.e., FNPO6–
9mm). FNPS and OV were assessed in the largest cross-sectional view of each ovary, as previously 
described by Christ et al.29 OV was estimated using the simplified formula for a prolate ellipsoid: 
0.5 × (transverse diameter) × (longitudinal diameter) × (anteroposterior diameter).29 Mean values 
between ovaries were tabulated for FNPO, FNPS, and OV. Women were then categorized as 
having PCOM according to current international consensus or proposed diagnostic thresholds (i.e., 
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FNPO2–9mm ≥ 20 follicles1; FNPS ≥ 9 follicles15; and OV ≥ 10 mL1). Notably, five investigators 
assessed the cineloops for the White cohort, and I assessed all of the cineloops for the South Asian 
cohort. I recognize that it would have been ideal for a single observer to assess all images, while 
blinded to race. However, use of the grid system method37 likely minimized potential variability 
and bias, as we have previously shown that the method yields excellent intra- and inter-rater 
agreement in follicle counts. Moreover, all six investigators were required to participate in a 
standardized training program and demonstrate strong inter-rater agreement (i.e., intra-class 
correlation coefficient >0.08) for an internal reliability assessment, prior to working with study 
data. Due to unforeseen differences in ultrasound scanning protocols between sites, I could not 
reliably estimate OV in 14 of the 31 South Asian women with PCOS. Therefore, data relating to 
ovarian size are presented for only 17 South Asian women with PCOS.  
 
Statistical Analysis. Statistical analyses were performed using JMP Pro 13 Statistical Software 
(SAS Institute, Cary, NC). The threshold for statistical significance was set a P < 0.05. Normality 
was determined using the Shapiro-Wilk W test. Most variables were not normally distributed; 
therefore, all data are reported as median (10th – 90th percentile). Differences in demographic, 
diagnostic, ovarian, and metabolic characteristics between the two cohorts were determined by 
two-sample t-tests (continuous, parametric variables), Mann-Whitney U tests (continuous, non-
parametric variables), or chi-squared tests (categorical variables), as appropriate. Within each 
cohort, relationships between reproductive / metabolic features and ovarian morphology were 
assessed by Spearman’s rank correlation coefficients.  
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RESULTS 
 
Demographic and Diagnostic Characteristics of Study Subjects. Demographic and diagnostic 
characteristics of each cohort are reported in Table 5. South Asian and White women with PCOS 
were similar in age (P = 0.95). There were no differences between groups in BMI (P = 0.16) or 
the proportion of women with overweight or obesity (P = 0.84). Both cohorts showed evidence of 
PCOS, as judged by menstrual cycle irregularity and clinical or biochemical hyperandrogenism 
(Table 4). Most women were diagnosed with hyperandrogenism based on elevated modified 
hirsutism scores. However, South Asian women with PCOS exhibited higher modified hirsutism 
scores (P = 0.04) and an increased prevalence of hirsutism compared to White women with PCOS 
(100% vs. 80%, respectively; P < 0.01). There were no differences between groups in the 
proportion of women with elevated total testosterone (P = 0.22) or AMH concentrations (P = 0.19).  
 
Table 5. Demographic and diagnostic characteristics of study subjects with PCOS 
 South Asian Cohort (n = 31) 
White Cohort 
(n = 30) P 
Age (y) 27 (21–30) 25 (20–34) 0.95 
BMI (kg/ m2) 27.2 (22.3–31.9) 29.2 (20.8–44.9) 0.16 
     Prevalence of overweight/obesity  22/31 (71%) 22/30 (73%) 0.84 
Prevalence of menstrual irregularities  31/31 (100%) 30/30 (100%) - 
Modified hirsutism score 10 (7–18) 9 (2–15) 0.04 
     Prevalence of clinical HA  31/31 (100%) 24/30 (80%) <0.01 
Total testosterone (ng/dL) 56.6 (38.6–94.7)a 52.1 (21.6–102.6) N/A 
     Prevalence of biochemical HA 4/25 (16%)a 9/30 (30%) 0.22 
AMH (ng/dL) 7.2 (2.1–12.2)a 9.7 (5.3–29.0)a N/A 
     Prevalence of abnormal AMH  1/15 (7%)a 6/27 (22%)a 0.19 
Data are presented as median (10th – 90th percentile) or n (%), where appropriate. Differences in raw data for total 
testosterone and AMH were not assessed. aData were not available for all study subjects. Abbreviations: BMI, body 
mass index; HA, hyperandrogenism; AMH, anti-Müllerian hormone; N/A not assessed. 
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Comparisons of Ovarian Morphology. Ultrasonographic markers of ovarian morphology are 
shown for each cohort in Table 6. South Asian women with PCOS exhibited lower OV compared 
to White women with PCOS (Median: 9.0 mL vs. 12.5 mL, respectively; P < 0.01), wherein the 
median value in the South Asian cohort fell below the current international diagnostic threshold 
(i.e., OV ≥ 10 mL). Consequently, the prevalence of PCOM, as indicated by OV, was lower in 
South Asian versus White women with PCOS (18% vs. 73%, respectively; P < 0.01). FNPO2–9 mm 
also tended to be lower in the South Asian cohort (P = 0.06). However, there were no differences 
between groups in the prevalence of PCOM by FNPO2–9 mm (P = 0.26), and median follicle counts 
in both groups exceeded the current international diagnostic threshold (i.e., FNPO ≥ 20).1 There 
were no differences between groups in FNPS, FNPO2–5 mm, or FNPO6–9 mm (All: P > 0.05). 
 
Table 6. Comparison of ovarian morphology between South Asian and White women with PCOS 
 South Asian Cohort (n = 31) 
White Cohort 
(n = 30) P 
OV (mL) 9.0 (4.8–10.6)a 12.5 (6.5–17.9) <0.01 
     Prevalence of PCOM by OV 3/17 (18%)a 22/30 (73%) <0.01 
FNPS 9 (5–13) 10 (5–17) 0.12 
     Prevalence of PCOM by FNPS 15/31 (48%) 18/30 (60%) 0.36 
FNPO2–9mm 31 (22–53)b 44 (16–84)c 0.06 
     Prevalence of PCOM by FNPO2–9mm 30/31 (96%)b 26/29 (90%)c 0.26 
FNPO2–5mm 29 (16–51)b 37 (14–77)c 0.12 
FNPO6–9mm 3 (0–8)b 5 (0–11)c 0.13 
Data are presented as median (10th – 90th percentile) or n (%), where appropriate. aReliable estimates of OV were 
only available for 17 of the 31 South Asian women with PCOS. bFNPO was likely underestimated due to compromised 
image quality. cData were missing for one subject due to technological malfunction. Abbreviations: OV, ovarian 
volume; FNPS, follicle number per section; FNPO, follicle number per ovary. 
 
Comparisons of Metabolic Features. Metabolic features of each cohort are described in Table 7. 
South Asian women with PCOS exhibited higher waist-to-hip ratios compared to White women 
with PCOS (Median: 0.92 vs. 0.87, respectively; P < 0.01). Although waist circumference did not 
differ between groups (P = 0.72), more women had elevated waist circumference (90% vs. 63% 
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respectively; P = 0.01) and elevated waist-to-hip ratio (100% vs. 57%, respectively; P < 0.01) in 
the South Asian cohort than in the White cohort. In addition, more women had elevated 2-hour 
glucose concentrations in the South Asian cohort than in the White cohort (56% vs. 10%, 
respectively; P < 0.01). Diastolic blood pressure tended to be lower in South Asian women with 
PCOS (P = 0.09), but there were no differences between groups in the prevalence of elevated 
diastolic blood pressure (P = 0.37). There were no differences between groups in systolic blood 
pressure or fasting glucose (All: P > 0.05). 
 
Table 7. Comparison of metabolic features between South Asian and White women with PCOS 
 South Asian Cohort 
(n = 31) 
White Cohort 
(n = 30) P 
Waist circumference (cm) 93 (78–100) 93 (68–132) 0.72 
     Prevalence of elevated WC 28/31 (90%) 19/30 (63%) 0.01 
Waist-to-hip ratio 0.92 (0.87–0.96) 0.87 (0.72–0.98) <0.01 
     Prevalence of elevated WHR 31/31 (100%) 17/30 (57%) <0.01 
Systolic BP (mmHg) 110 (110–130) 121 (98–138) 0.44 
     Prevalence of elevated systolic BP 1/31 (3%) 2/30 (7%) 0.53 
Diastolic BP (mmHg) 70 (60–80) 76 (57–93) 0.09 
     Prevalence of elevated diastolic BP 2/31 (6%) 4/30 (13%) 0.37 
Glucose, 0-hour (mg/dl) 98 (84–110)a 96 (85–116) N/A 
     Prevalence of elevated 0-hour glucose 7/19 (37%)a 10/30 (33%) 0.80 
Glucose, 2-hour (mg/dl) 144 (92–219)a 93 (69–154) N/A 
     Prevalence of elevated 2-hour glucose 15/27 (56%)a 3/30 (10%) <0.01 
Data are presented as median (10th – 90th percentile) or n (%), where appropriate. Differences in raw data for glucose 
were not assessed. aData were not available for all study subjects. Abbreviations: BP, blood pressure; N/A, not assessed. 
 
Correlations of Reproductive / Metabolic Features and Ovarian Morphology. Race-specific 
correlations between ovarian morphology and reproductive and metabolic features are presented 
in Table 8. Both South Asian and White women with PCOS showed significant correlations 
between OV and AMH, but the direction of the relationships were opposite in each cohort 
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(Spearman’s rho: –0.84 vs. 0.41, respectively; P < 0.05). FNPO2–9mm and FNPO2–5mm were 
positively correlated with AMH in the White cohort and with modified hirsutism score in the South 
Asian cohort (All: P < 0.05). FNPS was only positively correlated with AMH in the White cohort 
(P < 0.01). FNPO2–9mm and FNPO2–5mm had negative correlations with systolic and diastolic blood 
pressure in South Asian, but not White, women with PCOS (All: P < 0.05). Likewise, FNPS was 
also negatively correlated with systolic blood pressure in the South Asian cohort (P = 0.02). In 
White women with PCOS alone, OV was positively correlated with 2-hour glucose (P = 0.05) and 
FNPO6–9mm was negatively correlated with WHR (P = 0.04) as well as diastolic blood pressure (P 
= 0.03). 
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Table 8. Race-specific correlations between reproductive / metabolic features and ovarian morphology 
 OVa FNPS FNPO2–9mm FNPO2–5mm FNPO6–9mm 
 S. Asian White S. Asian White S. Asian White S. Asian White S. Asian White 
Modified hirsutism score -0.08 0.12 0.09 0.00 0.37 0.01 0.36 -0.02 0.03 0.18 
Total testosterone -0.51 0.21 0.14 -0.03 0.19 0.07 0.11 0.04 0.13 -0.01 
AMH -0.84 0.41 -0.03 0.58 -0.13 0.83 -0.08 0.84 -0.26 -0.07 
BMI -0.02 0.23 0.06 -0.18 -0.02 0.03 0.00 0.07 -0.20 -0.21 
Waist circumference -0.14 0.04 0.02 -0.25 0.01 -0.09 0.06 -0.04 -0.30 -0.35 
Waist-to-hip ratio -0.35 -0.01 0.06 -0.29 0.09 -0.05 0.17 0.01 -0.42 -0.38 
Systolic blood pressure -0.11 0.33 -0.43 0.03 -0.47 0.32 -0.43 0.36 0.07 -0.31 
Diastolic blood pressure 0.06 0.13 -0.33 -0.13 -0.51 0.14 -0.43 0.20 -0.18 -0.40 
Glucose, 0-hour  -0.41 0.28 0.28 -0.16 -0.12 0.10 0.04 0.14 -0.28 -0.28 
Glucose, 2-hour -0.45 0.36 0.18 -0.01 -0.15 0.21 -0.14 0.24 -0.01 -0.17 
Data are presented as Spearman’s rho. The shading reflects a significant or trending correlation: P < 0.01 (black), P < 0.05 (dark gray), P < 0.10 (light gray). 
aReliable estimates of OV were only available for 17 of the 31 South Asian women with PCOS. Abbreviations: BMI, body mass index; AMH, anti-Müllerian 
hormone. 
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DISCUSSION 
 
Summary. The present study aimed to determine differences in ovarian morphology between 
South Asian and White women with PCOS and whether or how these differences reflected 
reproductive or metabolic status. Such efforts have implications for understanding the impact of 
race and ethnicity on diagnostic thresholds for PCOM and for elucidating novel opportunities for 
ultrasound in the evaluation of PCOS globally. Data in the present study are unique in that I 
performed direct comparisons of ultrasonographic markers of ovarian morphology between South 
Asian and White cohorts using newer ultrasound technology and reliable measurement techniques. 
Overall, I detected lower OV in South Asian versus White women with PCOS, as well as 
unexpected, opposite correlations between PCOM and reproductive / metabolic features across 
cohorts. 
 
Race-Specific Differences in OV. To the best of my knowledge, the present study is the first to 
describe lower OV in South Asian versus White women with PCOS. My findings align with my 
hypothesis that estimates of OV would be lower in South Asian women. I reported a median OV 
of 9.0 mL in South Asian women with PCOS compared to 12.5 mL in White women with PCOS. 
Moreover, 82% of South Asian women with PCOS had OV < 10 mL, wherein a large proportion 
of the cohort did not meet the current international criteria for PCOM by OV. Only 27% of White 
women with PCOS had OV <10 mL. My findings are not surprising, given that previous diagnostic 
test studies have proposed thresholds of ³ 6 – 8 mL to adequately distinguish South Asian women 
with PCOS from South Asian women without PCOS.19,20 The proposed thresholds for South Asian 
women are substantially lower than the diagnostic threshold for OV (i.e., ³ 10 mL),1 which was 
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established in predominantly White cohorts.14 In clinical practice, false negative diagnoses could 
lead to missed opportunities for timely identification and treatment of comorbidities related to 
PCOS. Therefore, my findings support the need for a race-specific threshold for OV. Although 
FNPO is heralded as the best ultrasonographic marker of PCOS, there is still value in considering 
diagnostic thresholds for OV. Poor image quality and/or use of older imaging technology can 
compromise visualization of follicles within the ovary, and therefore, the reliability of FNPO to 
detect PCOM. In these cases, OV can be prioritized to diagnose PCOM.1,14,38 Ultimately, to 
confirm whether a lower diagnostic threshold is appropriate for South Asian women, future studies 
should include South Asian and White control groups. Both control cohorts are needed to identify 
thresholds that balance sensitivity and specificity for PCOS. The present study was not able to 
include controls, because the gynecologic primary care center in India, from which we acquired 
patient charts, does not see healthy women without PCOS. 
 
Race-Specific Differences in FNPO. The present study also appears to be the first to report a 
potential difference in FNPO between South Asian and White women with PCOS. I detected a 
lower median FNPO2–9mm of 31 follicles in South Asian women, compared to 44 follicles in White 
women, but the difference did not reach significance. The trend aligns with my hypothesis that 
estimates of FNPO would be lower in South Asian women. Previous diagnostic test studies have 
proposed thresholds of ³ 9–12 follicles throughout the entire ovary19,20 to adequately distinguish 
South Asian women with PCOS from those without PCOS. The proposed thresholds for FNPO in 
the South Asian population are substantially lower than the current diagnostic threshold (i.e., ³ 20 
follicles).1 It is important to acknowledge that FNPO was substantially higher among the South 
Asian women in the present study than in the studies by Ahmed et al. (Median: 13 follicles) and 
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Kar et al. (Mean: 20 follicles).19,20 I found that only 4% of South Asian women with PCOS had 
FNPO < 20 and could not detect differences between the two cohorts in the prevalence of PCOM 
by FNPO. I appreciate that utilization of the grid system method37 may have allowed me to conduct 
a more thorough analyses of the ovaries of South Asian women with PCOS, thereby leading to an 
increased follicle count compared to previous studies. Both Ahmed et al. and Kar et al. reported 
counting follicles by ‘scanning throughout the entire ovary,’ presumably in real time.19,20 
Emerging evidence from our group suggests that FNPO derived from real-time approaches is lower 
than FNPO derived from offline counts. Real-time counts are conducted while the patient is 
undergoing the ultrasound scan, likely leading to a need for faster-paced and less meticulous 
assessments. Without the ability to focus counts to a particular region of the ovary and flag the 
follicles that have already been counted, real-time counts could lead to under-estimates of FNPO. 
Therefore, OV may serve as a more reliable marker of PCOM, if offline follicle counts cannot be 
conducted in clinical settings.38 Nevertheless, my findings suggest that the current threshold for 
FNPO may be sufficient to detect PCOM in South Asian women. As with OV, future studies 
should include both South Asian and White control groups to corroborate the adequacy of the 
current thresholds in South Asian populations.  
 
Ovarian Morphology and AMH. AMH showed significant and positive correlations with FNPS 
(ρ = 0.58, P < 0.01), FNPO2-9mm (ρ = 0.83, P < 0.01), and FNPO2-5mm (ρ = 0.84, P < 0.01) in White 
women with PCOS. My findings were expected in light of existing evidence on AMH in PCOS. 
Previous studies have reported positive correlations between AMH and antral follicle count (i.e., 
FNPO × 2) in women with and without PCOS.39–42 AMH is produced by pre-antral and antral 
follicles (≤ 8 mm)39,43 and consequently believed to be an indirect biomarker of the ovarian 
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reserve.44 Women with PCOS have increased circulating concentrations of AMH, likely due to the 
increased number of small follicles in polycystic ovaries (i.e., 2 – 5 mm)31,40 and heightened per-
follicle production of AMH.45 Lack of a significant correlation with FNPO6–9mm (ρ = –0.07, P > 
0.10) is consistent with evidence of reduced numbers of medium-sized follicles (i.e., 6 – 9 mm) in 
PCOS.31 Surprisingly, AMH did not relate to follicle number or follicle size in South Asian women 
(All: ρ < 0.30, P > 0.10). Racial and ethnic differences in ovarian reserve, as reflected by AMH, 
have been reported across other populations and are thought to arise from a combination of genetic 
and environmental factors.46 The precise mechanisms remain unclear but could provide a 
physiologic basis for the presence of different relationships between AMH and FNPO in White 
versus South Asian women with PCOS. AMH also showed unexpected relationships with OV. I 
noted a moderate, positive correlation between AMH and OV in White women (ρ = 0.41, P < 
0.05), and a strong, negative correlation between AMH and OV in South Asian women (ρ = –0.84, 
P < 0.05). A consistent link between AMH and OV would add to the hormone’s clinical utility as 
a surrogate marker of PCOM.44 Race could mediate the relationship between AMH and ovarian 
size, but I suspect that the negative correlation in South Asian women with PCOS had more to do 
with the assay that our collaborator used to measure AMH. AMH is susceptible to substantial intra-
individual and inter-assay variation and most commercially available methods are considered 
unreliable.47 As a result, the International Evidence-Based Guideline for the Assessment and 
Management of PCOS recently concluded that AMH may have the potential to indicate PCOM, 
but not until the assays are standardized.1 
 
Ovarian Morphology and Blood Pressure. Systolic (ρ = –0.47, P < 0.01) and diastolic blood 
pressure (ρ = –0.51, P < 0.01) showed significant and negative correlations with FNPO2-9mm in 
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South Asian women with PCOS. My findings were unexpected, given that we did not find 
significant associations between blood pressure and follicle number in our previous study.29 I also 
noted a trending, positive association between systolic blood pressure and FNPO2-9mm in White 
women with PCOS (ρ = 0.32, P < 0.05). The opposing relationships with blood pressure across 
cohorts could be interpreted to mean that metabolic abnormalities have differential negative effects 
on follicle development across populations. However, it is important to mention that very few 
women in the present study had elevated systolic (South Asian: 3%; White: 7%) or diastolic blood 
pressure (South Asian: 6%; White: 13%) based on international diagnostic thresholds for 
hypertension.35 The narrow range of blood pressure measurements could have led to spurious 
findings and limits my ability to draw conclusions about any mediating effect of race on the 
relationship between blood pressure and ovarian morphology. 
 
Other Relationships. The remaining reproductive and metabolic features showed relatively weak 
correlations with follicle number, follicle size, and ovarian size (All: ρ < 0.50, P > 0.10). The 
direction of the relationships also differed across cohorts – to an extent that was difficult to explain. 
Of the reproductive features, modified hirsutism score was positively correlated with FNPO2-9mm 
and FNPO2-5mm in South Asian but not White women with PCOS. Androgens are produced by 
small follicles and believed to play an intra-ovarian role in follicular excess and anovulation in 
PCOS.48 As a result, previous studies have reported positive relationships between serum 
testosterone, FNPO2-9mm, and FNPO2-5mm.29,49 However, modified hirsutism score has not been 
consistently linked to follicle number or size. One reason could be that male-patterned hair growth 
reflects long-term exposure to elevated circulating androgens from any source (e.g., the ovaries or 
adrenal gland), while serum testosterone reflects current androgen status, and by extension, current 
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follicle populations.29,49 In the present study, South Asian women with PCOS had significantly 
higher modified hirsutism scores compared with White women, and all women in the South Asian 
cohort were diagnosed with PCOS based on clinical evidence of hyperandrogenism. Such 
characteristics may have contributed to my findings.  
 
Severity of Metabolic Disturbances. Of the metabolic features, poorer metabolic health (e.g., 
elevated waist-to-hip ratio and elevated diastolic blood pressure) were negatively correlated with 
FNPO6-9mm in White women with PCOS. My findings reaffirm those of our previous studies,29,30 
which showed that metabolic status may be involved in the regulation of antral follicle growth to 
dominance and ovulation. The absence of similar relationships in South Asian women with PCOS 
could reflect the relatively small numbers of 6 – 9 mm follicles (Mean: 3 follicles), which may 
have reduced my ability to detect correlations with metabolic features. The conflicting correlations 
across groups could also be explained by the overall good health of the two cohorts. Despite 
evidence of PCOS and abdominal obesity, most women in the present study had normal blood 
pressure and normal glucose concentrations. I might have been able to detect more consistent 
relationships had the women shown greater severity of reproductive and metabolic comorbidities. 
Nevertheless, a heightened prevalence of metabolic disturbances in the South Asian cohort 
supports current recommendations for lifestyle intervention as the first-line therapy in overweight 
/ obese women with PCOS.1 I appreciate that future studies in broader populations are ultimately 
needed to understand the role of ultrasonography in facilitating healthcare versus standard clinical 
metrics (e.g., BMI or waist circumference). 
 
Strengths and Limitations. The present study had two major strengths. First, to the best of my 
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knowledge, no other studies have directly compared ultrasonographic markers of PCOM across 
races. Evaluating the prevalence of PCOM based on current international diagnostic thresholds 
also allowed me to consider whether the current criteria are appropriate in South Asian women. 
My honors thesis can, therefore, be thought of as providing proof-of-concept for future studies to 
establish race-specific diagnostic thresholds for PCOM. Second, I used the grid system method to 
reliably determine FNPO in both cohorts. Such an approach allowed for meticulous analysis of the 
ovaries and reduced the impact of inter-method and inter-observer variability when comparing 
follicle data across races. However, the present study also had three main limitations. First, due to 
the retrospective design of the study, I was able to compare ovarian, reproductive, and metabolic 
features between 31 South Asian women with PCOS and 30 White women with PCOS. Post hoc 
sample size calculations revealed that I only had power (i.e., 0.80) to detect significant differences 
between groups in OV (α = 0.05) and correlations with effect sizes ≥ 0.5 (α = 0.05). It is possible 
that the unexpected findings across cohorts was influenced by the small sample size. An ideal 
study design would have included 64 women per group, because that number would have enabled 
me to confirm significant differences in FNPO and FNPS and detect correlations with weaker 
effect sizes (i.e., ~0.35). The inclusion of healthy controls of both races would also have 
strengthened the study. Efforts are ongoing in our group to acquire more patient records and 
confirm the relationships presented herein. Second, biochemical endpoints were evaluated with 
different assays across sites. It would have been challenging to use the same assays, because we 
were only able to receive medical charts and ultrasound scans (not sera) from our collaborator. I 
attempted to control for the impact of assay characteristics by calculating the prevalence of women 
with abnormal endocrine or metabolic values and by not combining reproductive / metabolic data 
for the correlation analysis. However, I cannot exclude the possibility that use of different assays 
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contributed to the unexpected, opposing relationships detected across cohorts. Finally, both study 
populations consisted of women with a narrow range of metabolic disturbances. Larger cohorts 
with more diverse metabolic statuses may have revealed greater differences in ovarian morphology 
between White and South Asian women with PCOS, as well as more striking correlations with 
reproductive / metabolic features. Because metabolic disturbances could manifest for a variety of 
reasons, future studies should explore any impacts of country of origin, country of residence, and 
lifestyle behaviors on correlations with ovarian morphology. 
 
CONCLUSION 
In summary, ovarian morphology differs between White and South Asian women with PCOS. My 
findings are consistent with recent international recommendations that urge for race and ethnicity 
to be considered in the diagnosis of PCOS.1,14 My results also indicate that South Asian women 
with PCOS have greater metabolic disturbances compared to White women with PCOS. Future 
studies in larger cohorts of South Asian and White women are ultimately needed to understand the 
utility of the ovary for reflecting systemic health across populations. Broadly, my findings 
highlight the importance of considering race in both the diagnosis and treatment of PCOS. 
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